MESSAGE BY THE CHAIRMAN
OF THE BOARD OF DIRECTORS

Dear Stakeholders,

The year 2025 was marked by a period in which the global economic landscape was reshaped, geopolitical risks increased, and financial markets experienced heightened volatility. Ongoing global uncertainties, cost pressures, and changes in the regulatory environment necessitated a more cautious and disciplined management approach within the pharmaceutical industry.

Despite this challenging environment, DEVA Holding maintained its stable position through its broad product portfolio and strong operational capabilities. According to IQVIA data, in 2025 we ranked 3 rd with a 4.5% market share by units and 7th with a 2.5% market share by value.

For 67 years, DEVA has been working to ensure access to healthcare for all. Guided by our responsibility to help build a healthy and sustainable future, we continue to strengthen our portfolio and expand our presence across therapeutic areas. In 2025, we further enhanced our product portfolio by adding 35 new products across 10 different therapeutic areas, increasing the diversity of our offering. With our reliable, effective, and affordable generic medicines, we continue to create value both in Türkiye and in international markets.

Our manufacturing facilities in Çerkezköy and Kartepe, with a total annual production capacity of 620 million units, once again successfully passed GMP inspections conducted by national and international health authorities during the year. At our facilities, which hold US FDA and EU GMP compliance approvals, we continue to manufacture in accordance with the highest quality standards. As of 2025, we reached 1,863 marketing authorizations across 86 countries. By strengthening our presence in regulated markets— particularly in European countries such as Germany and Switzerland, as well as in the United States—we further reinforced our international position.

At the core of our sustainable success lies the strategic importance we place on R&D. With our strong R&D infrastructure, state-of-the-art laboratories, and expert teams, we continue to develop products that meet the highest quality standards. We view our R&D investments not merely as a means of developing new products, but as a key driver of our long-term competitiveness.

We integrate our sustainability approach across all our processes, from production and supply chain management to human resources and social impact. Guided by the principles of efficient resource utilization, environmental responsibility, quality, and ethics, we adopt a management approach that considers not only today but also future generations.

In 2025, we took our sustainability approach a step further by publishing our first comprehensive sustainability report aligned with national regulatory frameworks. By presenting our environmental, social, and governance performance in a more measurable and comparable framework, we strengthened our corporate governance approach. We continue to treat sustainability as a strategic priority across all areas of our operations.

We are also strengthening our engagement with stakeholders by making our communication channels more accessible and better aligned with our corporate identity. Throughout 2025, we modernized our digital platforms to enhance our global brand visibility and expanded our international presence through new digital initiatives in additional markets. We regard digitalization as one of the fundamental drivers of sustainable value creation and global competitiveness.

Dear Stakeholders,

With our 67 years of experience, strong corporate structure, high production capacity, and growing global presence, we continue to move forward with determination in a rapidly changing world. Looking ahead, we will maintain our focus on operational efficiency and sustainable growth while continuing to contribute to global health and create lasting value for all our stakeholders.

With my deepest regards,

Philipp Haas

Chairman of the Board of Directors & CEO